Publications dans lesquelles il/elle collabore avec María Cristina Martínez Oharriz (21)

2024

  1. Mucus-penetrating and permeation enhancer albumin-based nanoparticles for oral delivery of macromolecules: Application to bevacizumab

    Drug Delivery and Translational Research, Vol. 14, Núm. 5, pp. 1189-1205

2023

  1. Gliadin nanoparticles for oral administration of bioactives: Ex vivo and in vivo investigations

    International Journal of Biological Macromolecules, Vol. 249

  2. Zein-based nanospheres and nanocapsules for the encapsulation and oral delivery of quercetin

    International Journal of Pharmaceutics, Vol. 643

2021

  1. Human serum albumin as a potential nanocarrier for the oral delivery of therapeutic proteins

    RESCIFAR Revista Española de Ciencias Farmacéuticas, Vol. 2, Núm. 2, pp. 15-17

2018

  1. Coencapsulation of cyclodextrins into poly(anhydride) nanoparticles to improve the oral administration of glibenclamide. A screening on C. elegans

    Colloids and Surfaces B: Biointerfaces, Vol. 163, pp. 64-72

  2. Cyclodextrin-grafted poly(anhydride) nanoparticles for oral glibenclamide administration. In vivo evaluation using C. elegans

    International Journal of Pharmaceutics, Vol. 547, Núm. 1-2, pp. 97-105

  3. Human serum albumin nanoparticles for ocular delivery of bevacizumab

    International Journal of Pharmaceutics, Vol. 541, Núm. 1-2, pp. 214-223

  4. Pegylated nanoparticles for the oral delivery of nimodipine: Pharmacokinetics and effect on the anxiety and cognition in mice

    International Journal of Pharmaceutics, Vol. 543, Núm. 1-2, pp. 245-256

2017

  1. A combination of nanosystems for the delivery of cancer chemoimmunotherapeutic combinations: 1-Methyltryptophan nanocrystals and paclitaxel nanoparticles

    Pharmacological Research, Vol. 126, pp. 77-83

  2. Nanoaggregation of inclusion complexes of glibenclamide with cyclodextrins

    International Journal of Pharmaceutics, Vol. 519, Núm. 1-2, pp. 263-271

  3. Optimization and evaluation of zein nanoparticles to improve the oral delivery of glibenclamide. In vivo study using C. elegans

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 121, pp. 104-112

  4. Supramolecular structure of glibenclamide and β-cyclodextrins complexes

    International Journal of Pharmaceutics, Vol. 530, Núm. 1-2, pp. 377-386

2004

  1. Fluconazole encapsulation in PLGA microspheres by spray-drying

    Journal of Microencapsulation, Vol. 21, Núm. 2, pp. 203-211

2002

  1. Solid dispersions of diflunisal-PVP: Polymorphic and amorphous states of the drug

    Drug Development and Industrial Pharmacy, Vol. 28, Núm. 6, pp. 717-725

1999

  1. Influence of polyethylene glycol 4000 on the polymorphic forms of diflunisal

    European Journal of Pharmaceutical Sciences, Vol. 8, Núm. 2, pp. 127-132

1998

  1. Solubilization and interaction of sulindac with polyvinylpyrrolidone K30 in the solid state and in aqueous solution

    Drug Development and Industrial Pharmacy, Vol. 24, Núm. 3, pp. 295-300

  2. Solubilization and interaction of sulindac with β-cyclodextrin in the solid state and in aqueous solution

    Drug Development and Industrial Pharmacy, Vol. 24, Núm. 3, pp. 301-306

1997

  1. Dissolution rate of polymorphs and two new pseudopolymorphs of sulindac

    Drug Development and Industrial Pharmacy, Vol. 23, Núm. 11, pp. 1095-1098

  2. Oxazepam dissolution rate from hydroxypropylmethylcellulose matrices

    Drug Development and Industrial Pharmacy, Vol. 23, Núm. 4, pp. 393-396

  3. Polymorphism of sulindac: Isolation and characterization of a new polymorph and three new solvates

    Journal of Pharmaceutical Sciences, Vol. 86, Núm. 2, pp. 248-251